Zhang et al. reported that CtBP2 was overexpressed in prostate cancer tissues and associated with poor outcome and several indicators of malignancy, including elevated serum PSA levels, advanced tumor stages and higher Gleason scores. This evidence concerns the gene CTBP2 and prostate carcinoma.